Safety and Efficacy of Itraconazole for the Treatment of Onychomycosis in the Diabetic Population.
- Author:
Won Young CHEY
1
;
Young Gull KIM
;
Eui Chang CHUNG
;
Ai Young LEE
Author Information
1. Department of Dermatology, Eulji Hospital, Eulji University School of Medicine, Seoul, Korea. chey68@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Diabetics;
Onychomycosis;
Safety;
Efficacy
- MeSH:
Communicable Diseases;
Diabetes Complications;
Dyspepsia;
Extremities;
Griseofulvin;
Humans;
Incidence;
Itraconazole*;
Ketoconazole;
Onychomycosis*;
Patient Compliance
- From:Korean Journal of Dermatology
2002;40(8):890-896
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
INTRODUCTION: As the number of diabetics increase with younger onset and longer duration, patients are confronted with higher incidence of diabetes related complications such as distal extremity vasculopathy, neuropathy and various infectious diseases. Such diabetics are more prone to a much higher rate of onychomycosis compared to normal subjects and because this could trigger irreversible consequences, confirmation of fungal involvement should be promptly taken care of. Itraconazole is a widely used drug nowadays and compared to drugs such as griseofulvin and ketoconazole, has many advantages in efficacy, cost, duration of therapy which eventually results in better patient compliance. OBJECTIVE: Our study was designed to better dictate the usage of itraconazole in diabetics so these patient can receive quality treatment when it is needed. METHOD: The study consisted of 101 patients with both onychomycosis and diabetes who were receiving treatment in Eulji hospital. They all received 3 pulses of itraconazole and were evaluated for efficacy and safety of their treatment. The patients were observed on routine examinations for 36 weeks and at their visits they were interviewed and received microscopic examinations. RESULT: Eighty four percent of the patients showed clinical and mycological improvement with 33% of them showing total clearance. There were no hypo- or hyperglycemic events and 17 patients complained of mostly mild side effects such as indigestion. Two patients dropped out of the study due to epigastric pain and peripheral extremity swelling. CONCLUSION: The use of itraconazole in the treatment of onychomycosis seemed to be effective and relatively safe for diabetics.
